Professional Documents
Culture Documents
Regimens For PCP Prophylaxis in Adults and Adolescents - UpToDate
Regimens For PCP Prophylaxis in Adults and Adolescents - UpToDate
www.uptodate.com © 2023 UpToDate, Inc. and/or its affiliates. All Rights Reserved.
Preferred regimen
Alternative regimens ◊
OR
OR
OR
Combination of: Δ
OR
Combination of: Δ
Dapsone 200 mg weekly plus Fever, rash, gastrointestinal upset,
methemoglobinemia, hemolytic
anemia (check for G6PD deficiency)
OR
A regimen that provides prophylaxis for PCP and toxoplasmosis should be administered to HIV-
infected patients who are IgG seropositive for toxoplasmosis AND have a CD4 count <100
cells/microL.
DS: double-strength oral tablet, 160 mg trimethoprim with 800 mg sulfamethoxazole; SS: single-
strength oral tablet, 80 mg trimethoprim with 400 mg sulfamethoxazole; G6PD: glucose-6-
phosphate dehydrogenase; PCP: Pneumocystis pneumonia; HIV: human immunodeficiency virus;
IgG: immunoglobulin G; TMP-SMX: trimethoprim-sulfamethoxazole.
* The doses recommended in the table are intended for patients with normal renal function; the
doses of some of these agents must be adjusted in patients with renal insufficiency.
◊ Of the alternative regimens for prevention of PCP, TMP-SMX three times weekly is generally
preferred. If patients cannot tolerate TMP-SMX, we prefer to use dapsone (or dapsone with
pyrimethamine and leucovorin for patients who require prophylaxis for toxoplasmosis) rather
than atovaquone. Dapsone is a sulfone that is usually tolerated by persons who have adverse
reactions to TMP-SMX. However, in patients who have had serious reactions to TMP-SMX (eg,
Stevens-Johnson syndrome/toxic epidermal necrolysis, rash with fever and systemic symptoms,
serum sickness, or hemolytic anemia), it may be prudent to avoid dapsone. Aerosolized
pentamidine should be used for PCP prophylaxis only when no other alternatives are available.
Adapted from: Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention
and treatment of opportunistic infections in HIV-infected adults and adolescents: Recommendations from the Centers
for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious
Diseases Society of America. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf (Accessed on June 23, 2017).